Will a warning label regarding potential suicide risks be added to Ozempic's labeling by June 30, 2024?
11
190Ṁ1131resolved Jul 2
Resolved
NO1D
1W
1M
ALL
This market resolves to 'yes' if Ozempic's manufacturer or the FDA announces the inclusion of a warning label regarding potential suicide risks before or on June 30, 2024. Such an announcement must appear on official communication channels or major news publications. The market end date is June 30, 2024.
This question is managed and resolved by Manifold.
Get
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ149 | |
| 2 | Ṁ35 | |
| 3 | Ṁ12 | |
| 4 | Ṁ5 | |
| 5 | Ṁ5 |
Related questions
Related questions
Will the Ozempic shortage be resolved on December 31st, 2025 according to the FDA?
87% chance
FDA issues statement/update on Ozempic NAION risk by March 31, 2025
4% chance
Will Ozempic be ranked within the top three prescribed drugs for diabetes by June 30, 2024?
2% chance
Will Ozempic be FDA approved for use in type 1 diabetes patients by end of 2024?
7% chance
Will there be a recall of Wegovy/Ozempic before 2035?
80% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
58% chance
Ozempic approval is revoked or withdrawn before 2031
6% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance